We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Urinalysis Test Market Driven by Increasing Prevalence of Chronic Kidney Disease and Diabetes

By LabMedica International staff writers
Posted on 14 Apr 2023

The global urinalysis test market is growing due to factors such as the rising prevalence of chronic diseases like chronic kidney disease and diabetes, an increase in the geriatric population, and heightened awareness about the importance of regular health checkups. More...

However, market growth is hindered by a shortage of skilled laboratory technicians. Nonetheless, the development of advanced urine analyzers is expected to create new growth opportunities in the near future. As a result, the global urinalysis test market, valued at USD 3.19 billion in 2021, is projected to experience a CAGR of 6.7% from 2022 to 2031, reaching USD 6.12 billion by 2031. These are the latest findings of Allied Market Research (Portland, OR, USA), a market research firm.

The COVID-19 pandemic adversely impacted the global urinalysis test market, as demand for urinalysis devices and consumables decreased due to lower hospitalization rates. Furthermore, sales of urinalysis tests declined during the early stages of the pandemic, and reduced hospital visits for urinalysis tests led to a decline in the adoption of urinalysis devices, thereby hampering market growth. However, the market has gradually recovered and is expected to grow steadily, primarily driven by the increasing incidence of urological disorders.

In 2021, the consumables segment held the largest share of the global urinalysis test market, accounting for over three-fourths of total revenue, and is expected to maintain its dominance throughout the forecast period. This segment is also projected to register the fastest CAGR of 6.9% during this time, owing to technological advancements in urinalysis consumables and high adoption of reagents and strips.

The disease screening segment held the largest share of the global urinalysis test market in 2021, accounting for over half of total revenue, and is expected to remain dominant throughout the forecast period. This segment is also expected to register the fastest CAGR of 7% during this time, mainly due to increased adoption of urinalysis devices for disease screening.

In 2021, the diagnostic laboratories segment accounted for the largest share of the global urinalysis test market, contributing around two-fifths of total revenue, and is expected to maintain its dominance throughout the forecast period. This segment is also expected to register the fastest CAGR of 7% during this time, primarily due to an increase in the prevalence of chronic diseases such as diabetes and kidney disease, which has led to a surge in demand for urinalysis tests among diagnostic laboratories.

Regionally, North America held the largest share of the global urinalysis test market in 2021, accounting for over two-fifths of total revenue, and is likely to continue dominating the market during the forecast period. Factors such as easy availability of diagnostic products, well-developed healthcare infrastructure, increased awareness about early disease diagnosis, and higher adoption of advanced diagnostic tools drive the growth of the North American urinalysis test market. However, the Asia-Pacific urinalysis test market is expected to register the fastest CAGR of 7.4% during the forecast period, driven by increased health awareness, development in healthcare infrastructure, and a surge in awareness of preventive healthcare in the region.

Related Links:
Allied Market Research


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Mini Vortex Mixer
Vornado
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The LIAISON PLEX® Gram-Positive Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.